Abstract.
Objective:
To determine the response to treatment and the long-term outcome of patients with the antisynthetase syndrome associated with anti-Jo-1-antibodies.
Patients and Methods:
A total of 12 patients with histologically proven myositis and anti-Jo-1-autoantibodies were evaluated over a mean follow-up period of 66.4 months. In all patients neuromuscular function tests, electromyographic examinations, pulmonary function tests and high-resolution-computed tomography of the lungs were performed regularly.
Results:
Muscle function improved in all patients with treatment, and a complete clinical response was achieved in 5 patients. Pulmonary function worsened in 1 patient, who died from respiratory failure, but normalised in 4 patients. Arthropathy progressed despite improvement of myositis and pulmonary status in 2 patients. Discontinuation of treatment was facilitated in 1 patient, although long-term therapy was required in 10 patients. In 2 patients with refractory disease, treatment with intravenous immunoglobulins was successful. Severe side effects of treatment occurred in 7 patients and overall mortality rate was one of 12 (8 %).
Conclusion:
The antisynthetase syndrome associated with anti-Jo-1-antibodies requires long-term immunosuppressive therapy in most patients. Whereas a complete clinical response of muscular symptoms is frequent, continued deterioration of the pulmonary system may occur despite immunosuppressive treatment, and may lead to fatal outcome. An interdisciplinary therapeutic approach is necessary for best possible results in these patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Angelini C, Menegazzo E, Fanin M (1993) Multifactorial study of inflammatory myopathies. Report of 29 cases. Ital J Neurol Sci 14:69–76
Arnett FC, Whelton JC, Zizic TM, Stevens MB (1973) Methotrexate therapy in polymyositis. Ann Rheum Dis 32:536–546
Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M (1981) The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 8:925–930
Arsura EL, Greenberg AS (1988) Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 18:29–37
Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91:162–168
Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38:1218–1224
Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH (1989) The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16:1225–1228
Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51:S37–45
Fischer E, Thiele A, Stierle HE, Lang B (1995) Anti-Jo-1-Antikörper: Spezifische Autoantikörper für Polymyositis mit interstitieller Lungenfibrose. 2 Fallvorstellungen [Anti-Jo-1 antibodies: specific autoantibodies for polymyositis with interstitial pulmonary fibrosis. 2 case reports]. Z Rheumatol 54:171–177
Gruhn WB, Diaz-Buxo JA (1987) Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 14:1045–1047
Haga HJ, D’Cruz D, Asherson R, Hughes GR (1992) Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 51:885–888
Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508
Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379–387
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70:360–374
Maeda K, Kimura R, Komuta K, Igarashi T (1997) Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 26:24–29
Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77:1019–1038
Mitsunaka H, Tokuda M, Hiraishi T, Dobashi H, Takahara J (2000) Combined use of cyclosporine A and methotrexate in refractory polymyositis. Scand J Rheumatol 29:192–194
Oddis CV (2000) Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12:492–497
Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:1762–1763
Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL (1998) Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 21:1668–1672
Targoff IN (2000) Update on myositisspecific and myositis-associated autoantibodies. Curr Opin Rheumatol 12:475–481
Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, Nemcova D, Charvat F (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102
Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399
Yoshida T, Koga H, Saitoh F, Sakamoto M,Harada M, Yoshida H, Sakisaka S, Sata M (1999) Pulse intravenous cyclophosphamide treatment for steroidresistant interstitial pneumonitis associated with polymyositis. Intern Med 38:733–738
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Späth, M., Schröder, M., Schlotter-Weigel, B. et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 251, 859–864 (2004). https://doi.org/10.1007/s00415-004-0449-5
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-004-0449-5